Dissolution in nasal fluid, retention and anti‐inflammatory activity of fluticasone furoate in human nasal tissue ex vivo

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Clinical and Experimental Allergy

• Publication date

  2009-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/j.1365-2222.2009.03306.xPMID 19538495
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs.

  2012cited by this paper
• Gene expression profiles of nasal polyps associated with allergic rhinitis.

  2009cited by this paper
• Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications

  2008cited by this paper
• Pharmacokinetic/pharmacodynamic profile of mometasone furoate nasal spray: potential effects on clinical safety and efficacy.

  2008cited by this paper
• Intranasal Mometasone Furoate Alleviates the Ocular Symptoms Associated with Seasonal Allergic Rhinitis: Results of a Post Hoc Analysis

  2008cited by this paper
• Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 *

  2008cited by this paper
• The role of cytokines in chronic rhinosinusitis with nasal polyps

  2008cited by this paper
• Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis.

  2008cited by this paper
• Nasal Mucosal Temperature in Relation to Nasal Airflow as Measured by Rhinomanometry

  2007cited by this paper
• Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate

  2007cited by this paper
• Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease.

  2007cited by this paper
• Differences in Endogenous Esterification and Retention in the Rat Trachea between Budesonide and Ciclesonide Active Metabolite

  2007cited by this paper
• Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis.

  2007cited by this paper
• Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.

  2007cited by this paper
• Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen

  2007cited by this paper
• Long‐term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis

  2007cited by this paper
• A correlative study of NF-κB activity and cytokines expression in human chronic nasal sinusitis

  2006cited by this paper
• Interleukin-4, Interleukin-8 and E-selectin Levels in Intranasal Polyposis Patients with and without Allergy: A Comparative Study

  2006cited by this paper
• The time course of the bilateral release of cytokines and mediators after unilateral nasal allergen challenge

  2005cited by this paper
• Topical corticosteroid inhibits interleukin‐4, ‐5 and ‐13 in nasal secretions following allergen challenge

  2005cited by this paper
• Significant receptor affinities of metabolites and a degradation product of mometasone furoate

  2004cited by this paper
• Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays

  2004cited by this paper
• Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate.

  2004cited by this paper
• Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease.

  2003cited by this paper
• Mometasone furoate degradation and metabolism in human biological fluids and tissues

  2003cited by this paper
• Permeability issues in nasal drug delivery.

  2002cited by this paper
• Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.

  2001cited by this paper
• Drug transfer through mucus.

  2001cited by this paper
• Presence of fluticasone propionate on human nasal mucosal surface and in human nasal tissue over a period of 24 h after intranasal application

  2001cited by this paper
• Binding of Glucocorticoids to Human Nasal Tissue in vitro

  2000cited by this paper
• Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray, and powder.

  1999cited by this paper
• Binding kinetics of budesonide to the human glucocorticoid receptor.

  1998cited by this paper
• Nasal delivery systems and their effect on deposition and absorption.

  1998cited by this paper
• A new collection method for the evaluation of nasal mucus proteins

  1998cited by this paper
• Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects.

  1997cited by this paper
• Proinflammatory cytokines: measurement in nasal secretion and induction of adhesion receptor expression.

  1995cited by this paper
• Nasal Mucosal Inflammation Has No Effect on the Absorption of Intranasal Triamcinolone Acetonide

  1994cited by this paper
• Activation of beclomethasone dipropionate by hydrolysis to beclomethasone‐17‐monopropionate

  1990cited by this paper
• Measurement of protein using bicinchoninic acid.

  1985cited by this paper
• Present possibilities for diagnosis in human nasal secretions.

  1983cited by this paper
• Solubility and dissolution of triamcinolone acetonide.

  1973cited by this paper
• Quantitative composition of nasal secretions in normal subjects.

  1972cited by this paper
• The ratio of range to standard deviation in the same normal sample

  1964cited by this paper
• THE DISTRIBUTION OF THE RATIO, IN A SINGLE NORMAL SAMPLE, OF RANGE TO STANDARD DEVIATION

  1954cited by this paper

• CFD-PK model for nasal suspension sprays: Validation with human adult in vivo data for triamcinolone acetonide.

  2024cites this paper
• In situ gelling nanosuspension as an advanced platform for fluticasone propionate nasal delivery.

  2022cites this paper
• Safety of intranasal corticosteroids for allergic rhinitis in children

  2022cites this paper
• Applicability of RPMI 2650 and Calu-3 Cell Models for Evaluation of Nasal Formulations

  2022cites this paper
• The API

  2021cites this paper
• The effect of ingredients commonly used in nasal and inhaled solutions on the secretion of mucus in vitro.

  2021influential citation
• Intranasal Corticosteroids: Topical Potency, Systemic Activity and Therapeutic Index

  2021cites this paper
• Quantitative Assessment of Pulmonary Targeting of Inhaled Corticosteroids Using Ex Vivo Receptor Binding Studies

  2020cites this paper
• Effects of low- versus high-dose fluticasone propionate/formoterol fumarate combination therapy on AMP challenge in asthmatic patients: A double-blind, randomised clinical trial.

  2016cites this paper
• Application of RPMI 2650 nasal cell model to a 3D printed apparatus for the testing of drug deposition and permeation of nasal products.

  2016cites this paper
• Development of a Novel Quantitative Structure-Activity Relationship Model to Accurately Predict Pulmonary Absorption and Replace Routine Use of the Isolated Perfused Respiring Rat Lung Model

  2016cites this paper
• Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations

  2016cites this paper
• Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis

  2016cites this paper
• Thermosensitive PLA based nanodispersion for targeting brain tumor via intranasal route.

  2016cites this paper
• A Hospital Based Comparative Clinical study between Mometasone Furoate and Fluticasone Furoate Nasal Spray for Allergic Rhinitis 1

  2016cites this paper
• Evaluation of the Transwell System for Characterization of Dissolution Behavior of Inhalation Drugs: Effects of Membrane and Surfactant.

  2015cites this paper
• Effect of some intranasal formulations used in the management of allergic rhinitis on mucociliary function

  2015cites this paper
• Suppression of Cytokine Release by Fluticasone Furoate vs. Mometasone Furoate in Human Nasal Tissue Ex-Vivo

  2014cites this paper
• Fluticasone Furoate Inhibits Cytokine Secretion from Nasal Epithelial Cells and Reduces Eosinophil Survival in an in vitro Model of Eosinophilic Inflammation

  2014cites this paper
• SOLUBILITY OF FLUTICASONE PROPIONATE IN AQUEOUS SOLUTIONS MEASURED BY A METHOD AVOIDING ITS ADSORPTION TO EXPERIMENTAL TOOLS

  2014cites this paper
• Effect of Nasal Anti-Inflammatory Treatment in Chronic Obstructive Pulmonary Disease

  2013cites this paper
• Dry Powder Inhalation Exposures of the Endotracheally Intubated Rat Lung, Ex Vivo and In Vivo: The Pulmonary Pharmacokinetics of Fluticasone Furoate

  2013cites this paper
• Subacute Rhinitis in Infants: Gastroesophageal Reflux Must Be Considered

  2013cites this paper
• Pharmacokinetic Evaluation of Intranasally Administered Vinyl Polymer-Coated Lorazepam Microparticles in Rabbits

  2012cites this paper
• Perioperative care for functional endoscopic sinus surgery

  2012cites this paper
• Perioperative care for functional endoscopic sinus surgery

  2012cites this paper
• Treatment of Allergic Rhinitis: Anticholinergics, Glucocorticotherapy, Leukotriene Antagonists, Omalizumab and Specific-Allergen Immunotherapy

  2012cites this paper
• Development of a novel model for comparative evaluation of intranasal pharmacokinetics and effects of anti-allergic nasal sprays.

  2012cites this paper
• Fluticasone furoate nasal spray is the only intranasal corticosteroid to reduce the ocular symptoms of seasonal allergic rhinitis consistently.

  2011cites this paper
• Vinyl polymer-coated lorazepam particles for drug delivery to the airways.

  2011cites this paper
• Oral immunotherapy: ready for prime time?

  2011cites this paper
• Intranasal lorazepam delivery 1 1 Vinyl polymers-coated lorazepam particles for potential intrananal delivery

  2011cites this paper
• Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells.

  2011cites this paper
• A review of the use of fluticasone furoate since its launch

  2011influential citation
• Fluticasone furoate/fluticasone propionate – different drugs with different properties

  2011cites this paper
• In Vitro Aqueous Fluid-Capacity-Limited Dissolution Testing of Respirable Aerosol Drug Particles Generated from Inhaler Products

  2010cites this paper
• Fluticasone furoate nasal spray: Profile of an enhanced-affinity corticosteroid in treatment of seasonal allergic rhinitis

  2010cites this paper
• Seasonal allergic rhinitis: fluticasone propionate and fluticasone furoate therapy evaluated

  2010cites this paper